Development of budesonide microparticles using spray-drying technology for pulmonary administration: Design, characterization, in vitro evaluation, and in vivo efficacy study

AAPS PharmSciTech

Volumn 10, Issue 3, 2009, Pages 993-1012

  Naikwade, Sonali R ^a   Bajaj, Amrita N ^a   Gurav, Prashant ^b   Gatne, Madhumanjiri M ^b   Singh Soni, Pritam ^c  

^a SNDT WOMEN S UNIVERSITY   (India)

^b BOMBAY VETERINARY COLLEGE   (India)

^c TATA MEMORIAL HOSPITAL   (India)

Author keywords

Budesonide; Dry powder inhaler; Gamma scintigraphy; Microparticles; Spray drying

Indexed keywords

BUDESONIDE; CHITOSAN; INTERLEUKIN 6; MICROSPHERE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DEACETYLATION; DIFFERENTIAL SCANNING CALORIMETRY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRY POWDER; EPITHELIUM CELL; GAMMA SCINTIGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; LUNG ALVEOLUS EPITHELIUM; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NORMAL HUMAN; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; RAT; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; SUSTAINED RELEASE FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY POWDER DIFFRACTION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; BUDESONIDE; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DESICCATION; EXCIPIENTS; HUMANS; LUNG; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RATS; REPRODUCIBILITY OF RESULTS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 70449519069     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9290-6     Document Type: Article

References (87)

1. SJ Szefler 1999 Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid J Allergy Clin Immunol 104 S175 S183 10.1016/S0091-6749(99)70059-X 1:CAS:528:DyaK1MXnsFSntbc%3D
2. I Basyigit F Yildiz SK Ozkara E Yildirim H Boyaci A Ilgazli 2005 Addition of inhaled corticosteroid on combined bronchodilator therapy in patients with COPD Pulm Pharmacol Ther 20 1 5
3. M Cazzola 2006 Single inhaler budesonide/formoterol in exacerbations of chronic obstructive pulmonary disease Pulm Pharmacol Ther 19 79 89 15964228 10.1016/j.pupt.2005.03.004 1:CAS:528:DC%2BD28XhsFKlsQ%3D%3D (Pubitemid 43052994)
4. L Thorsson O Borga S Edsbacker 1999 Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder Br J Clin Pharmacol 47 619 624 10383539 10.1046/j.1365-2125.1999.00956.x 1:CAS:528:DyaK1MXktFSmtLY%3D (Pubitemid 29257659)
5. TP Learoyd JL Burrows E French PC Seville 2008 Chitosan-based spray-dried respirable powders for sustained delivery of terbutaline sulfate Eur J Pharm Biopharm 68 224 234 17560772 10.1016/j.ejpb.2007.04.017 1:CAS:528: DC%2BD1cXlsF2msQ%3D%3D
6. J Fu J Fiegel E Krauland J Hanesa 2002 New polymeric carriers for controlled drug delivery following inhalation or injection Biomaterials 23 4425 4433 12219833 10.1016/S0142-9612(02)00182-5 1:CAS:528:DC%2BD38XmtVSrsLw%3D (Pubitemid 34888047)
7. K Koushik UB Kompella 2004 Particle & device engineering for inhalation drug delivery Drug Deliv Technol 4 40 50 1:CAS:528: DC%2BD2cXivFymtbo%3D
8. AJ Ribeiro C Silva D Ferreira F Veiga 2005 Chitosan-reinforced alginate microspheres obtained through the emulsification/internal gelation technique Eur J Pharm Biopharm 25 31 40 1:CAS:528:DC%2BD2MXjs1Knu7k%3D (Pubitemid 40602193)
9. V Sanna N Kirschvink P Gustin E Gavini I Roland L Delattre, et al. 2003 Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration AAPS PharmSciTech 5 1 7
10. M Irngartinger V Camuglia M Damm J Goede HW Frijlink 2004 Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturing Eur J Pharm Biopharm 58 7 14 15207532 10.1016/j.ejpb.2004.03.016 1:CAS:528:DC%2BD2cXltVGht7Y%3D (Pubitemid 38780999)
11. RN Jashnani PR Byron RN Dalby 1995 Testing of dry powder aerosol formulations in different environmental conditions Int J Pharm 113 123 130 10.1016/0378-5173(94)00197-D 1:CAS:528:DyaK2cXms1entb8%3D (Pubitemid 24323042)
12. ML Sommerville AJ Hickey 2003 Aerosol generation by metered-dose inhalers containing dimethyl ether/propane inverse microemulsions AAPS PharmSciTech 4 1 7 10.1208/pt040458
13. CL Leach PJ Davidson RJ Boudreau 1998 Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone Eur Respir J 12 1346 1353 9877489 10.1183/09031936.98. 12061346 1:CAS:528:DyaK1MXlt1Wqsw%3D%3D (Pubitemid 29011427)
14. MB Chougule BK Padhi KA Jinturkar A Misra 2007 Development of dry powder inhalers Recent Patents on Drug Delivery and Formulation 1 11 21 19075871 10.2174/187221107779814159 1:CAS:528:DC%2BD2sXjtlCkurw%3D
15. KA Johnson 1997 Preparation of peptide and protein powders for inhalation Adv Drug Deliv Rev 26 3 15 10837528 10.1016/S0169-409X(97)00506-1 1:CAS:528:DyaK2sXjsVKht7Y%3D (Pubitemid 27288480)
16. Z Yu TL Rogers J Hu KP Johnston RO Williams 2002 Preparation and characterization of microparticles containing peptide produced by a novel process: spray freezing into liquid Eur J Pharm Biopharm 54 221 228 12191695 10.1016/S0939-6411(02)00050-4 1:CAS:528:DC%2BD38XmtlKjtL8%3D (Pubitemid 34919397)
17. XM Zeng GP Martin SK Tee C Marriott 1998 The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro Int J Pharm 176 99 110 10.1016/S0378-5173(98)00300-7 1:CAS:528:DyaK1cXntlymtLg%3D (Pubitemid 28544976)
18. H Larhrib GP Martin C Marriott D Prime 2003 The influence of carrier and drug morphology on drug delivery from dry powder formulations Int J Pharm 257 283 296 12711183 10.1016/S0378-5173(03)00156-X 1:CAS:528:DC%2BD3sXjtVemsL8%3D (Pubitemid 36507054)
19. IJ Smith MP Billings 2003 The inhalers of the future? A review of dry powder devices on the market today Pulm Pharmacol Ther 16 79 95 12670777 10.1016/S1094-5539(02)00147-5 1:CAS:528:DC%2BD3sXisFWlsbg%3D (Pubitemid 36372063)
20. AB Schnurch 2000 Chitosan and its derivatives: potential excipients for peroral peptide delivery systems Int J Pharm 194 1 13 10.1016/S0378-5173(99) 00365-8
21. RO Cook RK Pannu IW Kellaway 2005 Novel sustained release microspheres for pulmonary drug delivery J Control Release 104 79 90 15866336 10.1016/j.jconrel.2005.01.003 1:CAS:528:DC%2BD2MXjvVClsLY%3D (Pubitemid 40615237)
22. FM Spoelstra DS Postma H Hovenga JA Noordhoek HF Kauffman 2000 Budesonide and formoterol inhibit ICAM-1 and VCAM-1 expression of human lung fibroblasts Eur Respir J 15 68 74 10678623 10.1183/09031936.00.15106800 1:CAS:528: DC%2BD3cXhtFSnt78%3D (Pubitemid 30068938)
23. I Uings I Puxeddu V Temkin SJ Smith D Fattah KP Ray, et al. 2005 Effects of dexamethasone on TNF-alpha-induced release of cytokines from purified human blood eosinophils Clin Mol Allergy 3 5 9 15857511 10.1186/1476-7961-3-5 (Pubitemid 41522130)
24. LA Sorbera L Martin PA Leeson 2000 Treatment of IBD: anti-TNF-α MAb Drugs Future 25 669 673 10.1358/dof.2000.025.07.585694 1:CAS:528: DC%2BD3cXntFOitrw%3D
25. BS Kang EY Chung YP Yun MK Lee YR Lee KS Lee, et al. 2001 Inhibitory effects of anti-inflammatory drugs on interleukin-6 bioactivity Biol Pharm Bull 24 701 703 11411563 10.1248/bpb.24.701 1:CAS:528:DC%2BD3MXktFygt7g%3D (Pubitemid 32586664)
26. S Escotte O Tabary D Dusser CM Teboul E Puchelle J Jacquot 2003 Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis bronchial epithelial cells via IKK-β kinase pathway Eur Respir J 21 574 581 12762338 10.1183/09031936.03.00031803 1:CAS:528:DC%2BD3sXks1agsLw%3D
27. IM Smirnov K Bailey CH Flowers NW Garrigues LJ Wesselius 1999 Effects of TNF-α and IL-1β on iron metabolism by A549 cells and influence on cytotoxicity Am J Physiol 277 L257 L263 10444519 1:CAS:528:DyaK1MXls1antLo%3D
28. JH Toogood J Baskerville B Jennings NM Lefcoe SA Johansson 1989 Bioequivalent doses of budesonide and prednisone in moderate and severe asthma J Allergy Clin Immunol 84 688 700 2681331 10.1016/0091-6749(89)90297-2 1:STN:280:DyaK3c%2FjvVSrtQ%3D%3D (Pubitemid 20008500)
29. AK Kamada SJ Szefler RJ Martin HA Boushey VM Chinchilli JM Drazen, et al. 1996 Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network Am J Respir Crit Care Med 153 1739 1748 8665030 1:STN:280: DyaK283nvFOmtQ%3D%3D
30. T Miyamoto T Takahashi S Nakajima S Makino M Yamakido K Mano 2000 A double-blind, placebo-controlled dose-response study with budesonide Turbuhaler in Japanese asthma patients Respirology 5 247 256 11022987 10.1046/j.1440-1843. 2000.00256.x 1:STN:280:DC%2BD3cvmvVWhtg%3D%3D (Pubitemid 30743934)
31. W Busse P Chervinsky J Condemi WR Lumry TL Petty S Rennard 1998 Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma J Allergy Clin Immunol 101 457 463 9564797 10.1016/S0091-6749(98)70353-7 1:CAS:528: DyaK1cXivVSqurg%3D (Pubitemid 28208248)
32. KI van den Brink M Boorsma Staal-van den Brekel AJ S Edsbäcker EF Wouters L Thorsson 2008 Evidence of the in vivo esterification of budesonide in human airways Br J Clin Pharmacol 66 27 35 18384442 10.1111/j.1365-2125.2008. 03164.x 1:CAS:528:DC%2BD1cXptVKju7s%3D (Pubitemid 351836039)
33. S Edsbacker R Brattsand 2002 Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data Ann Allergy Asthma Immunol 88 609 616 12086369
34. A Tronde M Gillen L Borgstrom J Lotvall J Ankerst 2008 Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD J Clin Pharmacol 48 1300 1308 18974284 10.1177/0091270008322122 1:CAS:528:DC%2BD1cXhtlyrs7bI
35. M Joshi A Misra 2001 Dry powder inhalation of liposomal ketotifen fumarate: formulation and characterization Int J Pharm 223 15 27 11451628 10.1016/S0378-5173(01)00705-0 1:CAS:528:DC%2BD3MXkvFygu7g%3D (Pubitemid 32640874)
36. SP Shah A Misra 2004 Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance AAPS PharmSciTech 5 1 7 10.1208/pt050465
37. SR Naikwade RN Meshram AN Bajaj 2009 Preparation and in vivo efficacy study of pancreatin microparticles as enzyme replacement therapy for pancreatitis Drug Dev Ind Pharm 35 417 432 18850362 10.1080/03639040802422104 1:CAS:528:DC%2BD1MXkvVyitbY%3D
38. R Wakode R Bhanushali A Bajaj 2008 Development and evaluation of push-pull based osmotic delivery system for pramipexole PDA J Pharm Sci Tech 62 22 31 1:CAS:528:DC%2BD1cXjt1yqsL8%3D
39. N Amrutiya A Bajaj M Madan 2009 Development of microsponges for topical delivery of mupirocin AAPS PharmSciTech 10 402 409 10.1208/s12249-009-9220-7 19381834 10.1208/s12249-009-9220-7
40. SR Naikwade PP Kulkarni SR Jathar AN Bajaj 2008 Development of time and pH dependent controlled release colon specific delivery of tinidazole DARU 16 119 127
41. SR Naikwade AN Bajaj 2008 Development and evaluation of once a day oral controlled multiparticulate drug delivery systems of cefixime trihydrate Indian J Pharm Educ Res 42 283 294
42. Patel V, Patel M, Patel R. Chitosan: a unique pharmaceutical excipient. Drug Deliv Technol. 2005;5(6). http://www.drugdeliverytech.com.
43. A Baxter M Dillon KDA Taylor GAF Roberts 1992 Improved method for I.R. determination of the degree of N-acetylation of chitosan Int J Biol Macromol 14 166 169 1390449 10.1016/S0141-8130(05)80007-8 1:CAS:528:DyaK38XkslSitb0%3D
44. GS Zijlstra M Rijkeboer DJ Drooge M Sutter W Jiskoot MV Weert, et al. 2007 Characterization of a cyclosporine solid dispersion for inhalation AAPS J 9 E190 E199 17614361 10.1208/aapsj0902021 (Pubitemid 47007410)
45. YC Huang CH Chiang MK Yeh 2003 Optimizing formulation factors in preparing chitosan microparticles by spray-drying method J Microencapsul 20 247 260 12554378 10.1080/02652040210162522 1:CAS:528:DC%2BD3sXnt1ygsA%3D%3D (Pubitemid 36240618)
46. T Sebti K Amighi 2006 Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation Eur J Pharm Biopharm 63 51 58 16380243 10.1016/j.ejpb.2005.11.003 1:CAS:528:DC%2BD28XjtFGhurg%3D
47. PWS Heng LW Chan LT Lim 2000 Quantification of the surface morphologies of lactose carriers and their effect on the in vitro deposition of salbutamol sulphate Chem Pharm Bull 48 393 398 10726864 1:CAS:528:DC%2BD3cXhslahsLk%3D
48. DO Corrigan AM Healy OI Corrigan 2006 Preparation and release of salbutamol from chitosan and chitosan co-spray dried compacts and multiparticulates Eur J Pharm Biopharm 62 295 305 16314079 10.1016/j.ejpb.2005. 09.008 1:CAS:528:DC%2BD28Xit1Chu7w%3D (Pubitemid 43356579)
49. DO Corrigan AM Healy OI Corrigan 2003 The effect of spray drying solutions of bendroflumethiazide/polyethylene glycol on the physicochemical properties of the resultant materials Int J Pharm 262 125 137 12927394 10.1016/S0378-5173(03)00338-7 1:CAS:528:DC%2BD3sXmtFaksrg%3D (Pubitemid 36966700)
50. KB Prinn HR Costantino M Tracy 2002 Statistical modeling of protein spray drying at the lab scale AAPS PharmSciTech 3 1 6 10.1208/pt030104
51. PH Hirst GR Pitcairn JG Weers TE Tarara AR Clark LA Dellamary, et al. 2002 In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler Pharm Res 19 258 264 11934231 10.1023/A:1014482615914 1:CAS:528:DC%2BD38XisFGgurc%3D (Pubitemid 34211841)
52. F Ungaro GD Rosa A Miro F Quaglia MIL Rotonda 2006 Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs Eur J Pharm Sci 28 423 432 16806857 10.1016/j.ejps.2006.05.005 1:CAS:528:DC%2BD28XntFWrtbw%3D (Pubitemid 44038350)
53. M Skiba F Bounoure C Barbot P Arnaud M Skiba 2005 Development of cyclodextrin microspheres for pulmonary drug delivery J Pharm Pharmaceut Sci 8 409 418 1:CAS:528:DC%2BD2MXhtFWlsL%2FL
54. AHD Boer P Hagedoorn D Gjaltema J Goede HW Frijlink 2004 Air classifier technology (ACT) in dry powder inhalation part 1: introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures Int J Pharm 260 187 200
55. T Cerchiara B Luppi G Chidichimo F Bigucci V Zecchi 2005 Chitosan and poly(methyl vinyl ether-co-maleic anhydride) microparticles as nasal sustained delivery systems Eur J Pharm Biopharm 61 195 200 16006107 10.1016/j.ejpb.2005. 05.005 1:CAS:528:DC%2BD2MXhtFWhtrjF (Pubitemid 41427627)
56. SK Jain GP Agrawal NK Jain 2006 Evaluation of porous carrier-based floating orlistat microspheres for gastric delivery AAPS PharmSciTech 7 E1 E9 16584139 10.1208/pt070490
57. SR Naikwade AN Bajaj 2008 Development of validated specific HPLC method for budesonide and characterization of its alkali degradation product Can J Anal Sci Spect 53 113 122 1:CAS:528:DC%2BD1MXovFamtLo%3D
58. AH Jansson C Eriksson X Wang 2005 Effects of budesonide and N-acetylcysteine on acute lung hyperinflation, inflammation and injury in rats Vascul Pharmacol 43 101 111 15967733 10.1016/j.vph.2005.03.006 1:CAS:528:DC%2BD2MXmsVOntL4%3D (Pubitemid 40981938)
59. T Kouno N Katsumata H Mukai M Ando T Watanabe 2003 Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan Jpn J Clin Oncol 33 309 313 12913086 10.1093/jjco/hyg062 (Pubitemid 43115258)
60. ML Landry S Cohen K Huber 1997 Comparison of EDTA and acid-citrate-dextrose collection tubes for detection of cytomegalovirus antigenemia and infectivity in leukocytes before and after storage J Clin Microbiol 35 305 306 8968934 1:STN:280:DyaK2s7itlKrtQ%3D%3D
61. TF Leung CK Wong CWK Lam AM Li GWK Wong TF Fok 2003 Plasma TARC concentration may be a useful marker for asthmatic exacerbation in children Eur Respir J 21 616 620 12762345 10.1183/09031936.03.00083303 1:CAS:528: DC%2BD3sXks1agsLY%3D
62. M Baek HS Chung Y Kim DH Kim 1999 Disposition and metabolism of 2-(2(1,3-dioxolan-2-yl)-2-methyl-4-(2-oxopyrrolidin-1-yl)-6-nitro-2h-1- benzopyran (Skp-450) in rats Drug Metab Dispos 27 510 516 10101146 1:CAS:528:DyaK1MXislShtL8%3D
63. K Kronkvist M Gustavsson AK Wendel H Jaegfeldt 1998 Automated sample preparation for the determination of budesonide in plasma samples by liquid chromatography and tandem mass spectrometry J Chromatogr 823 401 409 10.1016/S0021-9673(98)00592-5 1:CAS:528:DyaK1cXmtl2mt7o%3D (Pubitemid 28463506)
64. K Deventer P Mikulkova HV Hoecke PV Eenoo FT Delbeke 2006 Detection of budesonide in human urine after inhalation by liquid chromatography-mass spectrometry J Pharm Biomed Anal 42 474 479 16842962 10.1016/j.jpba.2006.05.016 1:CAS:528:DC%2BD28Xps1Cisrg%3D (Pubitemid 44375111)
65. H Kaiser D Aaronson R Dockhorn S Edsbacker P Korenblat A Kallen 1999 Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler Br J Clin Pharmacol 48 309 316 10510140 10.1046/j.1365-2125.1999.00008.x 1:CAS:528:DyaK1MXmsFehs7w%3D (Pubitemid 29417712)
66. MA Faouzi T Dine M Luyckx C Brunet B Gressier M Cazin, et al. 1995 High-performance liquid chromatographic method for the determination of budesonide in bronchoalveolar lavage of asthmatic patients J Chromatogr 664 463 467 10.1016/0378-4347(94)00473-I 1:CAS:528:DyaK2MXktFCjsrs%3D
67. AM Larsson P Jansson A Runström R Brattsand 2000 Prolonged airway activity and improved selectivity of budesonide possibly due to esterification Am J Respir Crit Care Med 162 1455 1461
68. TV Vyve P Chanez JY Lacoste J Bousquet FB Michel P Godard 1992 Comparison between bronchial and alveolar samples of bronchoalveolar lavage fluid in asthma Chest 102 356 361 1643913 10.1378/chest.102.2.356
69. M Jendbro CJ Johansson P Strandberg H Falknilsson S Edsbacker 2001 Pharmacokinetics of budesonide and its major ester metabolite after inhalation and intravenous administration of budesonide in the rat Drug Metab Dispos 29 769 776 11302946 1:CAS:528:DC%2BD3MXjtF2jurg%3D
70. R Gandhi CL Kaul R Panchagnula 2004 Pharmacokinetic evaluation of an azithromycin controlled release dosage form in healthy human volunteers: a single dose study Int J Pharm 270 1 8 14726116 10.1016/j.ijpharm.2003.09.046 1:CAS:528:DC%2BD2cXit1Chtg%3D%3D (Pubitemid 38077081)
71. S Lewis G Subramanian S Pandey N Udupa 2006 Design, evaluation and pharmacokinetic study of mucoadhesive buccal tablets of nicotine for smoking cessation Indian J Pharm Sci 68 829 831 10.4103/0250-474X.31030 1:CAS:528:DC%2BD2sXlslKkt7g%3D
72. R Donnelly JP Seale 2001 Clinical pharmacokinetics of inhaled budesonide Clin Pharmacokinet 40 427 440 11475468 10.2165/00003088-200140060-00004 1:CAS:528:DC%2BD3MXlvFajsbs%3D
73. PN Yadav Z Liu MM Rafi 2003 A diarylheptanoid from lesser galangal (Alpinia officinarum) inhibits proinflammatory mediators via inhibition of mitogen-activated protein kinase, p44/42, and transcription factor nuclear factor-{kappa}B J Pharmacol Exp Ther 305 925 931 12626645 10.1124/jpet.103. 049171 1:CAS:528:DC%2BD3sXkt1SnsLg%3D (Pubitemid 36617969)
74. JR Henry KC Rupert JH Dodd IJ Turchi SA Wadsworth DE Cavender, et al. 1998 Potent inhibitors of the MAP kinase p38 Bioorg Med Chem Lett 8 3335 3340 9873730 10.1016/S0960-894X(98)00589-7 1:CAS:528:DyaK1cXotFagtbk%3D
75. BMG Wilson A Severn NT Rapson J Chana P Hopkins 1991 A convenient human whole blood culture system for studying the regulation of tumor necrosis factor release by bacterial lipopolysaccharide J Immunol Methods 139 233 240 1904465 10.1016/0022-1759(91)90193-J 1:CAS:528:DyaK3MXltlenu7g%3D
76. C Monn S Becker 1999 Cytotoxicity and induction of proinflammatory cytokines from human monocytes exposed to fine (PM2.5) and coarse Particles (PM10-2.5) in outdoor and indoor air Toxicol Appl Pharmacol 155 245 252 10079210 10.1006/taap.1998.8591 1:CAS:528:DyaK1MXhvVahs7w%3D (Pubitemid 29153372)
77. UB Kompella N Bandi SP Ayalasomayajula 2003 Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression Invest Ophthalmol Vis Sci 44 1192 1201 12601049 10.1167/iovs.02-0791 (Pubitemid 36297840)
78. AK Greenberg J Hu S Basu J Hay J Reibman T Yie, et al. 2002 Glucocorticoids inhibit lung cancer cell growth through both the extracellular signal-related kinase pathway and cell cycle regulators Am J Respir Cell Mol Biol 27 320 328 12204894 1:CAS:528:DC%2BD38XmvFOkt70%3D
79. Y Fujitani A Trifilieff 2003 In vivo and in vitro effects of SAR 943, a rapamycin analogue, on airway inflammation and remodeling Am J Respir Crit Care Med 167 193 198 12406821 10.1164/rccm.200205-455OC (Pubitemid 36076079)
80. SP Newman GR Pitcairn PH Hirst L Rankin 2003 Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs Adv Drug Deliv Rev 55 851 867 12842604 10.1016/S0169-409X(03)00081-4 1:CAS:528:DC%2BD3sXkvFektr4%3D (Pubitemid 36776797)
81. DJ Ball PH Hirst SP Newman B Sonet B Streel F Vanderbist 2002 Deposition and pharmacokinetics of budesonide from the Miat Monodose inhaler, a simple dry powder device Int J Pharm 245 123 132 12270249 10.1016/S0378-5173(02)00338-1 1:CAS:528:DC%2BD38XntFygsrg%3D (Pubitemid 35299898)
82. GR Pitcairn G Hooper X Luria X Rivero SP Newman 1997 A scintigraphic study to evaluate the deposition patterns of a novel antiasthma drug inhaled from the Cyclohaler dry powder inhaler Adv Drug Deliv Rev 26 59 67 10837533 10.1016/S0169-409X(97)00511-5 1:CAS:528:DyaK2sXjsVKhtL0%3D (Pubitemid 27288485)
83. E Bondesson T Bengtsson L Borgström LE Nilsson K Norrgren E Trofast, et al. 2003 Planar gamma scintigraphy-points to consider when quantifying pulmonary dry powder aerosol deposition Int J Pharm 258 227 240 12753769 10.1016/S0378-5173(03)00148-0
84. Z Lee M Ljungberg RF Muzic MS Berridge 2001 Usefulness and pitfalls of planar γ-scintigraphy for measuring aerosol deposition in the lungs: a Monte Carlo investigation J Nucl Med 42 1077 1083 11438631 1:STN:280: DC%2BD3MzotVykuw%3D%3D
85. E Bondesson T Bengtsson L Borgstrom LE Nilsson K Norrgren E Trofast, et al. 2003 Planar gamma scintigraphy-points to consider when quantifying pulmonary dry powder aerosol deposition Int J Pharm 251 33 47 12527173 10.1016/S0378-5173(02)00579-3 1:CAS:528:DC%2BD3sXis1WhsQ%3D%3D (Pubitemid 36071458)
86. MJ Myers JP Lavender JB Deoliviera A Maseri 1981 A simplified method of quantitating organ uptake using a gamma camera Br J Radiol 54 1062 1067 6794702 10.1259/0007-1285-54-648-1062 1:STN:280:DyaL38%2FkslKnug%3D%3D
87. GR Pitcairn SP Newman 1997 Tissue attenuation corrections in gamma scintigraphy J Aerosol Med 10 187 198 10.1089/jam.1997.10.187